Opioid REMS Should Go Further And Focus On Drug Diversion, Consultants Say
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA public meeting features presentations of how track and trace technology can help prevent abuse of pain killers.
You may also be interested in...
As Opioid REMS Meeting Nears, FDA Notes Worry About Shifting Use To Different Class
In NEJM editorial, FDA's Woodcock suggests "unintended consequences" of any risk management plan for the pain products.
As Opioid REMS Meeting Nears, FDA Notes Worry About Shifting Use To Different Class
In NEJM editorial, FDA's Woodcock suggests "unintended consequences" of any risk management plan for the pain products.
REMS For Opioids Still Has A Long Road Ahead; Advisory Committee Is Likely
A finalized Risk Evaluation and Mitigation Strategy for opioids is a long way off - possibly more than a year - and FDA expects additional stakeholder and industry meetings, as well as a multidisciplinary advisory committee to take place before a program is set in stone